Self-efficacy is associated with a lower probability of damage accrual in patients with systemic lupus erythematosus: data from the Almenara Lupus Cohort.

IF 3.4 4区 医学 Q2 RHEUMATOLOGY
Claudia Elera-Fitzcarrald, Rocío V Gamboa-Cardenas, Victor Pimentel-Quiroz, Cristina Reategui-Sokolova, José Alfaro-Lozano, Zoila Rodriguez-Bellido, Cesar Pastor-Asurza, Risto Perich-Campos, Graciela S Alarcón, Manuel F Ugarte-Gil
{"title":"Self-efficacy is associated with a lower probability of damage accrual in patients with systemic lupus erythematosus: data from the Almenara Lupus Cohort.","authors":"Claudia Elera-Fitzcarrald, Rocío V Gamboa-Cardenas, Victor Pimentel-Quiroz, Cristina Reategui-Sokolova, José Alfaro-Lozano, Zoila Rodriguez-Bellido, Cesar Pastor-Asurza, Risto Perich-Campos, Graciela S Alarcón, Manuel F Ugarte-Gil","doi":"10.55563/clinexprheumatol/fdf5zj","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the association between self-efficacy and damage accrual in SLE patients.</p><p><strong>Methods: </strong>We evaluated SLE patients from the Almenara Lupus Cohort. Self-efficacy was ascertained with the six instruments of the Patient-Reported Outcomes Measurement Information System® (PROMIS®) Self-efficacy for Managing Chronic Conditions. For PROMIS instruments, the higher score, the greater self-efficacy. Damage was assessed with the SLICC/ACR damage index (SDI). Generalised estimating equations were performed, using as the outcome any increase in the SDI and the self-efficacy instrument in the previous visit; multivariable models were adjusted for possible confounders measured at the same visit as the self-efficacy instrument. OR was reported per 5 units increase per self-efficacy instrument component.</p><p><strong>Results: </strong>A total of 209 patients and 563 visits were included. At baseline, mean general self-efficacy was 47.2 (10.4), self-efficacy for managing emotions was 44.6 (8.0), for managing symptoms was 47.7 (8.2), for managing daily activities was 45.5 (7.5), for managing social interactions was 42.9 (7.9) and for managing medications and treatment was 43.9 (7.0). During the follow-up visits, 41 (19.6%) patients accrued damage once and 2 patients (1.0%) accrued it twice. In the multivariable models, a better self-efficacy for managing symptoms and daily activities were predictive of less damage accrual (OR=0.79, 95% CI=0.64-0.98 and OR=0.71, 95% CI=0.54-0.95, respectively).</p><p><strong>Conclusions: </strong>A better self-efficacy mainly in the managing symptoms and daily activities domains is predictive of a lower risk of damage accrual, even after adjusting for possible confounders. Strategies to improve self-efficacy in SLE patients should be encouraged to improve patients' outcomes.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.55563/clinexprheumatol/fdf5zj","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To evaluate the association between self-efficacy and damage accrual in SLE patients.

Methods: We evaluated SLE patients from the Almenara Lupus Cohort. Self-efficacy was ascertained with the six instruments of the Patient-Reported Outcomes Measurement Information System® (PROMIS®) Self-efficacy for Managing Chronic Conditions. For PROMIS instruments, the higher score, the greater self-efficacy. Damage was assessed with the SLICC/ACR damage index (SDI). Generalised estimating equations were performed, using as the outcome any increase in the SDI and the self-efficacy instrument in the previous visit; multivariable models were adjusted for possible confounders measured at the same visit as the self-efficacy instrument. OR was reported per 5 units increase per self-efficacy instrument component.

Results: A total of 209 patients and 563 visits were included. At baseline, mean general self-efficacy was 47.2 (10.4), self-efficacy for managing emotions was 44.6 (8.0), for managing symptoms was 47.7 (8.2), for managing daily activities was 45.5 (7.5), for managing social interactions was 42.9 (7.9) and for managing medications and treatment was 43.9 (7.0). During the follow-up visits, 41 (19.6%) patients accrued damage once and 2 patients (1.0%) accrued it twice. In the multivariable models, a better self-efficacy for managing symptoms and daily activities were predictive of less damage accrual (OR=0.79, 95% CI=0.64-0.98 and OR=0.71, 95% CI=0.54-0.95, respectively).

Conclusions: A better self-efficacy mainly in the managing symptoms and daily activities domains is predictive of a lower risk of damage accrual, even after adjusting for possible confounders. Strategies to improve self-efficacy in SLE patients should be encouraged to improve patients' outcomes.

自我效能感与系统性红斑狼疮患者较低的损伤累积概率相关:来自Almenara狼疮队列的数据。
目的:评价SLE患者自我效能感与损害累积的关系。方法:我们评估了来自Almenara狼疮队列的SLE患者。自我效能感通过患者报告结果测量信息系统®(PROMIS®)管理慢性病自我效能感的六种工具来确定。对于PROMIS工具,得分越高,自我效能感越强。用SLICC/ACR损伤指数(SDI)评价损伤程度。使用广义估计方程,将SDI和自我效能仪在上次访问中的任何增加作为结果;对多变量模型进行调整,以排除在与自我效能仪相同的访问中测量的可能的混杂因素。每增加5个单位,每个自我效能仪成分报告OR。结果:共纳入209例患者,就诊563次。基线时,平均一般自我效能为47.2(10.4),管理情绪的自我效能为44.6(8.0),管理症状的自我效能为47.7(8.2),管理日常活动的自我效能为45.5(7.5),管理社会互动的自我效能为42.9(7.9),管理药物和治疗的自我效能为43.9(7.0)。随访期间,41例(19.6%)患者出现1次损伤,2例(1.0%)患者出现2次损伤。在多变量模型中,管理症状和日常活动的更好的自我效能预示着更少的损害累积(OR=0.79, 95% CI=0.64-0.98和OR=0.71, 95% CI=0.54-0.95)。结论:即使在对可能的混杂因素进行调整后,主要在管理症状和日常活动领域的更好的自我效能也预示着较低的损害累积风险。应鼓励提高SLE患者自我效能感的策略,以改善患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.10
自引率
18.90%
发文量
377
审稿时长
3-6 weeks
期刊介绍: Clinical and Experimental Rheumatology is a bi-monthly international peer-reviewed journal which has been covering all clinical, experimental and translational aspects of musculoskeletal, arthritic and connective tissue diseases since 1983.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信